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ABSTRACT 
The synthesis of multivalent systems based on hexakis-adducts of [60]fullerene employing a 
biocompatible copper-free click chemistry strategy has been accomplished. A symmetric hexakis-
adduct of fullerene bearing 12 maleimide units 3 is reported and it has been employed to carry out the 
thiol-maleimide Michael addition. To achieve orthogonal click addition, an asymmetric derivative 
bearing one maleimide and ten cyclooctynes has been synthesized. The sequential and one-pot 
transformations of the two clickable groups have been explored, finding the best results in the case of 
the one-pot experiment. This route has been used to obtain a biocompatible hexakis-adduct appended 
with two different biomolecules, carbohydrates and amino acids. 
 
INTRODUCTION 
Multivalency has a crucial role in many biological processes, such as cell-cell, cell adhesion 
or cell-virus interactions.1-3 It may be described as a strategy to achieve strong non-covalent 
interactions through multiple otherwise weak interactions between ligands and receptors. It is 
strongly related with biomolecular recognition where the resulting global interaction is 
stronger than the sum of the interactions of a monovalent ligand. Different supramolecular 
processes as chelation, clustering, subsite rebinding or statistical rebinding seem to be involved 
in the multivalent effect giving rise to stronger and highly selective recognition events.2 Hence, 
in the last years there has been an interest in the formation of multivalent systems for the 
presentation of ligands to different receptors.3 For the achievement of this goal, different 
platforms have been employed that allow the formation of multivalent clusters,4 such as 
dendrimers,5,6 nanoparticles,7 aromatics,8 polymers,9 liposomes,10 graphene,11,12 nanotubes13,14 
or fullerenes15-17 among others. 
Their remarkable features make [60]fullerene hexakis-adducts suitable platforms for the 
construction of multivalent systems, including their monodisperse globular disposition of the 
ligands, due to a Th octahedral symmetry.18  It is important to note that size and shape are 
important issues to address in the presentation of multivalent systems. Actually, they can even 
play a most significant role than multivalency itself. In this regard, the previously synthesized 
polyvalent bacteriophage-based glycodendrinanoparticle displaying 1620 copies of mannose 
on its surface19 exhibited around 18 times less efficiency (IC50 value) than a tridecafullerene 
having 120 mannoses.15 The synthesis of these derivatives was first reported by Hirsch20 and 
later modified by Sun21 and is carried out in one-step by the Bingel addition of the 
corresponding malonates. This route, however, is limited by the steric effects of the 
functionalized malonates, usually proceeding with moderate to low yields. To circumvent this 
limitation, a two-step procedure is usually carried out, functionalizing in the first step the C60 
surface with simple malonates which are lately post-functionalized in the second step.22-26 
Nierengarten and our own group have developed a two-step click-chemistry approach to obtain 
complex hexakis-adducts.27-29 In the first step, an alkyne or azide functionalized malonate is 
added to the C60 core, obtaining the hexakis-adduct which is then chemically modified by the 
Cu(I)-catalyzed alkyne azide 1,3-dipolar cycloaddition (CuAAC). This methodology has led 
to derivatives for applications in different areas, such as materials science30,31 and especially 
for biological applications.32-35 However, the employ of copper is a serious drawback for the 
biocompatibility of the obtained products. Generally, an additional purification step is needed 
to eliminate the residual copper. Moreover, when the obtained molecules have copper chelating 
groups, a small amount of this metal remains chelated to the molecule after several purification 
steps.36 This is more noticeable in the case of multivalent systems in which there are many of 
those chelating groups which, in some cases, could affect to the click reaction, lowering the 
yields and even, in some cases, inhibiting the reaction. 
Recently, we have reported the synthesis of a [60]fullerene hexakis-adduct appended with 
cyclooctynes to carry out copper-free strain promoted alkyne-azide cycloadditions (SPAAC).37 
In the present work, we describe the synthesis of a new derivative for the copper-free click 
chemistry on hexakis-adducts of fullerene, a system bearing 12 maleimide units. Although the 
thiol-ene click reaction had already been employed in the post-functionalization of hexa-
adducts of [60]fullerene by the introduction of up to twelve methacrylate subunits, the yields 
obtained in the addition of different thiols (AIBN, benzene, 80ºC) were moderate (35-52%).38 
Using the thiol-maleimide Michael addition, the scope of this procedure has been tested with 
some thiols of different nature and the yields were above 95% in all cases under mild 
conditions. Then, the introduction of the two mentioned clickable units, a maleimide and ten 
cyclooctyne units in the same molecule to achieve orthogonal click chemistry has been 
explored. Two different sequential routes and the one-pot approach have been studied to carry 
out both click transformations on the same molecule, opening the way to interesting hexakis-
adducts of fullerene with two different functionalities obtained by a copper-free methodology. 
As a proof of concept, two kinds of biomolecules, as carbohydrates and amino acids, have been 
successfully clicked following this biocompatible approach.  
 
RESULTS AND DISCUSSION 
The synthesis of maleimide hexakis-adduct of [60]fullerene was carried out as depicted in 
Scheme 1.  
 
 
Scheme 1. Reagents and conditions: (i) H2, Pd-C, DCM/MeOH, r.t., overnight (100%); (ii) 
DMAP/DCC, DCM/DMF, r.t., overnight (99%). 
 
Scheme 2. Reagents and conditions: (i) DMF, r.t., 30 min (96-100 %). 
 
As previously observed for the cyclooctyne appended hexakis-adduct,37 direct addition of the 
corresponding malonate by Bingel reaction under the conditions reported by Sun yielded a 
complex mixture of different products owing to bromination of the maleimide unit. Therefore, 
we followed a three steps strategy involving formation of the hexakis-adduct with protected 
alcohols 1a,37 deprotection to yield 1b and esterification with 3-maleimidepropionic acid (2) 
in the presence of DCC and DMAP (Scheme 1). Purification of the hexakis-adduct 3 was 
developed by size-exclusion chromatography using Sephadex (DCM:MeOH 1:1). Employing 
the thiol-maleimide click reaction, we proved the platform for the conjugation of different 
thiols, as non-polar 1-octanethiol (4a), polar 2-(2-(2-mercaptoethoxy)ethoxy)ethan-1-ol (4b) 
and the protected amino acid N-acetyl-L-cysteine methyl ester (4c) (Scheme 2). A mixture of 
3 (1 eq) and the corresponding thiol (1.5 eqs per maleimide unit) in DMF was kept at room 
temperature for 30 min. After purification using Sephadex, derivatives 5a-c were obtained in 
excellent yields.  
The structure of compounds 5a-c was confirmed by 1H NMR and 13C NMR spectroscopy. 
DEPT, COSY and HSQC experiments were carried out for all new compounds synthesized to 
confirm the proposed structures (see ESI). The 1H NMR spectra of these conjugates clearly 
show completion of the addition of the thiols by the disappearance of the characteristic signal 
of the olefinic protons of the maleimide at δ 6.71. The addition of the thiol generates a new 
asymmetric centre per maleimide unit, leading to a complex mixture of diastereoisomers owing 
to the multivalent presentation of the systems. However, the high symmetry of these hexakis-
adducts provides NMR spectra simpler than those we can expect. For 5a and 5b, the signals 
for the proton of the new stereogenic centre are indistinguishable for the two possible isomers 
and only one signal is observed at 3.72 and 3.94 ppm, respectively. For compound 5c, on the 
other side, a diastereomeric mixture per maleimide unit is formed upon addition of the thiol, 
and therefore the signals of the cysteine and the maleimide moieties appear duplicated (see 
ESI). 13C NMR spectra of 5a-c also confirm the structure showing the presence of only two 
signals for the sp2 carbons of [60]fullerene at  145 and 141 ppm and the loss of the signal of 
the olefinic carbons of the maleimide observed at  134 ppm (Figure 1). 
Once we had prepared the symmetric adduct 3, we were interested in obtaining an asymmetric 
derivative for the simultaneous addition of different addends to the C60 scaffold. To improve 
the biocompatibility of the resulted systems, we thought of an orthogonal copper-free click 
reaction. Thus, maleimide and cyclooctyne units were introduced in the same molecule by 
following the synthetic pathway depicted in Scheme 3. Monoadduct 8 was first synthesized 
under typical Bingel addition conditions, adding malonate 7 (1 eq), I2 (3.5 eqs) and DBU (2.5 
eqs) to a solution of C60 (2 eqs). Formation of the asymmetric hexakis-adduct was carried out 
by addition of the malonate 9 with orthogonal protection of the alcohol group (10 eqs) in the 
presence of a large excess of CBr4 (80 eqs) and DBU (20 eqs). Hydrogenation at atmospheric 
pressure of compound 10 led to quantitative deprotection of the benzyl groups to yield 
compound 11, which was submitted to esterification with the cyclooctyne carboxylic acid 12 
in the presence of DCC and DMAP. The deprotection of the TBDPS was achieved by the 
HF/pyridine complex in the presence of AcOH and a final esterification with maleimide 
carboxylic acid 2 yielded compound 15. 
Characterization by 1H NMR and 13C NMR of all derivatives confirmed the proposed 
structures. Even for the asymmetric hexakis-adducts of C60 10-15, only two signals were 
observed in the 13C NMR spectrum for the 48 sp2 carbons of the fullerene core in the 
compounds, showing the high local symmetry of these derivatives, as previously reported 
(Figure 2).29,39,40 
Then, the reactivity of compound 15 was explored either in a stepwise sequence (routes A and 
B, Scheme 4) or in a one-pot process (route C, Scheme 4)). First, the SPAAC addition of 2-(2-
(2-azidoethoxy)ethoxy)ethan-1-ol to the cyclooctyne moieties was carried out. The previously 
reported conditions for this addition (DMSO, MW, 50°C) were avoided to prevent reaction of 
the azide with the maleimide, which can take place at high temperature. Thus, the SPAAC 
reaction was accomplished in DMSO at room temperature overnight and led quantitatively to 
compound 16 after size-exclusion chromatography with Sephadex LH-20. Completion of the 
reaction was confirmed by the absence of the signals of the alkyne functionality of the 
cyclooctyne units in the 13C NMR spectrum (Figure 2). Additionally, the characteristic 
formation of two regioisomers was observed, with several duplicated signals present in the 1H 
NMR (see ESI).  
 
 
 
Figure 1. 13C NMR spectra of symmetric hexakis-adducts 3 and 5b (CDCl3, 125.8 MHz). 
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Scheme 3. Reagents and conditions: i) ethyl malonyl chloride, Et3N, DMAP, DCM, r.t., overnight 
(quant.); ii) C60, DBU, I2, ODCB, 0 ºC, 4h (69%); iii) DBU, CBr4, ODCB, r.t., 72h (48%); iv) H2, 
Pd/C, EtOAc/MeOH, r.t., overnight (quant); v) DMAP, DCC; DCM/DMF, r.t., overnight (99%); vi) 
HF/py, AcOH, TFH, r.t., overnight (99%); vii) DMAP, DCC, DCM, r.t., overnight (quant.). 
 
The signals corresponding to the two carbons of the triazole rings were also duplicated, 
appearing at δ  145 and 135 for the major isomer and δ  144 and 133 for the minor isomer. 
Importantly, the signals of the olefinic carbons of the maleimide unit were also present at δ  
134, which confirms the exclusive functionalization of the cyclooctyne moieties under these 
conditions (Figure 2). Treatment of compound 16 with 1-octanethiol in DMF at room 
temperature, under the same conditions employed for the synthesis of 5a-c, did not lead to the 
quantitative conversion to 17a, as the signal corresponding to the maleimide protons was 
present in the 1H NMR spectrum. Therefore, temperature and time reaction were increased (24 
h, 50ºC) and an excess of thiol was added (10 eqs). Even under these conditions, the maleimide 
unit remained unreacted. 
Therefore, we went through route B (Scheme 4). Compound 15 was submitted to the thiol-
maleimide coupling reaction, yielding quantitatively compound 18. The 1H NMR spectrum 
showed the presence of the signals corresponding to the generated asymmetric centre and the 
diastereotopic protons of the methylene unit close to the chiral carbon. In addition, the signals 
of the alkyne carbons of the cyclooctynes were still present at δ  100 and 93, evidencing the 
chemoselectivity of the reaction (Figure 2). Then, reaction of 18 with 2-(2-(2-
azidoethoxy)ethoxy)ethan-1-ol was carried out under microwave irradiation for 30 min and led 
to compound 17a in quantitative yield. In this case, the reaction could be run under microwave 
irradiation as it was not necessary to avoid the side reaction of the azide with the maleimide 
unit. The 13C NMR spectrum shows the signals of the new triazole rings for the two 
regioisomers formed, as well as the absence of the signals of the triple bond, thus showing the 
completion of the SPAAC addition. Consequently, route B allowed the formation of derivative 
17a with excellent yield and complete orthogonality of the two clickable units. 
Finally, we explored the one-pot approach to the synthesis of 17a, employing the same solvent 
for the two reactions (DMF) and avoiding the purification of the intermediate compound 18. 
According to the previous results, it is important to add first the thiol derivative. Hence, we 
treated a solution of 15 in DMF with 1-octanethiol and, after 30 min, 2-(2-(2-
azidoethoxy)ethoxy)ethan-1-ol was added and the mixture was submitted to MW irradiation 
for 30 min. After size-exclusion chromatography, compound 17a was obtained in quantitative 
yield. In conclusion, route C seems to be the more adequate to the preparation of derivatives 
bearing two different addends around the C60 scaffold. 
As a proof of concept to check the scope of this methodology with more complex derivatives, 
we synthesized compound 17b, in which an amino acid and ten carbohydrate units have been 
clicked to the fullerene scaffold using the route C. A solution of compound 15 in DMF was 
treated with the cysteine derivative 4c and, after 30 min, the azide mannose 19 was added and 
the mixture submitted to MW irradiation at 50°C for 30 min. After purification with G-25, 
compound 17b was obtained quantitatively. The 13C NMR spectrum of the isolated product 
revealed the absence of the signals of the alkyne groups or the olefinic carbons of the 
maleimide, as well as the characteristic signal for the anomeric carbon of the mannose at δ  
100 (Figure 2) 
 
Scheme 4. Explored conditions for the sequential or one-pot copper-free click 
functionalization of asymmetric hexakis-adduct 15. 
 
Figure 2. 13C NMR spectra of compounds 15, 16, 18 and 17b (125.8 MHz) 
 
CONCLUSIONS 
In conclusion, in this work we have prepared two highly versatile building blocks for the 
synthesis of new hexakis-adducts of [60]fullerene under copper-free click chemistry 
conditions. Firstly, we have obtained a symmetric maleimide derivative 3 which results useful 
for the thiol-maleimide Michael addition. Secondly, we have synthesized an asymmetric 
hexakis-adduct endowed with two orthogonal clickable moieties. Compound 15 contains a 
maleimide unit and ten cyclooctyne units that can be independently modified in a stepwise or 
a one-pot process. Remarkably, the one-pot procedure allows the preparation of the 
orthogonally clicked adducts in an effective way without the need to purify the intermediate 
products. The scope of the methodology has been tested with biologically interesting addends, 
as carbohydrates and amino acids, allowing to get mixed adducts with these two types of 
compounds. Moreover, the two processes are carried out in the absence of copper as catalyst, 
which is a key point for the biocompatibility of the new conjugates. This kind of derivatives 
could be of interest for several biological applications for which carbohydrates should be added 
as recognition motifs to address and facilitate the internalization of the appropriate epitope 
depending on the biological target.  
EXPERIMENTAL SECTION 
General. Reagents and solvents were purchased as reagent grade and used without further 
purification. Compounds 1a-b,37 3-maleimidopropionic acid (2),41 2-[2’-(2’’-
mercaptoethoxy)ethoxy]ethanol (4a),42 4-((tert-butyldiphenylsilyl)oxy)butan-1-ol (7),43 bis (4-
(benzyloxy)butyl) malonate (9),37 cyclooctyne derivative 12,37 2-[2’-(2’’-
azidoethoxy)ethoxy]ethanol44 and compound 1945 were prepared according to previously reported 
procedures. For column chromatography silica gel 60 (230-400 mesh, 0.040-0.063 mm) was 
purchased from E. Merck or by Sephadex LH20 or G25 (GE Healthcare, Barcelona, Spain) gel 
filtration. Thin Layer Chromatography (TLC) was performed on aluminium sheets coated with silica 
gel 60 F254 purchased from E. Merck, visualization by UV light. IR spectra (cm-1) were measured on 
an ATI Mattson Genesis Series FTIR instrument. NMR spectra were recorded on a Bruker AC 400 or 
AC 500 with solvent peaks as reference. 1H and 13C NMR spectra were obtained for solutions in 
CD3OD, CDCl3 and DMSO-d6. All the assignments were confirmed by one- and two-dimensional 
NMR experiments (COSY, HSQC and DEPT). Some signals appear duplicated due to the mixture of 
isomers and are indicated in the list by mj. for major and mi. for minor isomers. MALDI-TOF-mass 
spectra were carried out on a Bruker BIFLEXTM matrix-assisted laser desorption time-of-flight mass 
spectrometer using dithranol or 2-[(E)-3-(4-tert-butylphenyl)-2methylprop-2-
enylidene]propanedinitrile (DCTB) as matrix. ESI-mass spectra were recorded with an Esquire 6000 
ESI-Ion Trap from Bruker Daltonics using CH2Cl2/MeOH as solvent system. Melting points were 
measured with a Gallenkamp (Sanyo) melting point apparatus. Microwave irradiation experiments 
were performed using a Monowave 300 (Anton Pear) apparatus. The temperature in the sealed reaction 
vessel was monitored by an external surface sensor. 
Synthesis and Characterization 
Compound 3. To a solution of 1b (100 mg, 45.48 μmol) and 3-maleimidopropionic acid (2) 
(138 mg, 0.82 mmol) in a mixture dry CH2Cl2/DMF (20:1, 4.2 mL) under Ar atmosphere, a solution 
of DCC (171 mg, 0.82 mmol) in dry CH2Cl2 (2 mL) and DMAP (3.5 mg, 27.29 μmol) were 
sequentially added. The reaction mixture was stirred at room temperature overnight. Once the reaction 
was completed, the dicyclohexylurea was filtered off in a fritted glass filter and washed with CH2Cl2. 
The crude product was purified by size-exclusion chromatography (Sephadex LH-20, MeOH/CH2Cl2 
1:1), to give 3 (180 mg, 44.87 μmol, 99%) as a red oil. FTIR: 2958, 1703, 1205 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 6.71 (s, 24H, Hmaleimide), 4.29 (t, 24H, JH,H = 6.3, OCH2CH2), 4.08 (t, 24H, JH,H = 6.0, 
CH2CH2OCO), 3.81 (t, 24H, JH,H = 7.0, NCH2CH2), 2.64 (t, 24H, JH,H = 7.0, NCH2CH2), 1.76 (m, 24H, 
OCH2CH2), 1.69 (m, 24H, CH2CH2OCO); 13C NMR (125.8 MHz, CDCl3) δ: 170.6 (COester), 170.3 
(COmaleimide), 163.6 (CO), 145.7 (Csp2,fullerene), 141.0 (Csp2,fullerene), 134.2 (CHmaleimide), 69.0 (Csp3,fullerene), 
66.4 (OCH2CH2), 64.0 (CH2CH2OCO), 45.3 (Cq), 33.6 (NCH2CH2), 32.8 (NCH2CH2), 25.1 
(OCH2CH2) 25.0 (CH2CH2OCO); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C210H168N12O72Na 
4034.7; Found 4034.1. 
 
Thiol-maleimide conjugation 
General procedure. 
To a solution of maleimide [60]fullerene hexakis adduct 3 (80 mg, 19.96 μmol) in DMF (2 mL), 
compound 4a-c (1.5 eq. per maleimide group) was added. After 30 min of stirring at room temperature, 
the solution was purified by size-exclusion chromatography (Sephadex LH-20, CH2Cl2/MeOH 1:1), 
furnishing the compound 5a-c. 
 
Compound 5a. Following the general procedure and using 1-octanethiol (4a) (53 mg, 0.36 
mmol) as starting material, compound 5a (110 mg, 19.09 μmol, 96%) was obtained as a red oil. FTIR: 
2927, 2855, 1778, 1702, 1190, 728 cm-1; 1H NMR (500 MHz, CDCl3) δ: 4.30 (m, 24H, OCH2CH2), 
4.08 (m, 24H, CH2CH2OCO), 3.79 (m, 24H, NCH2CH2), 3.72 (m, 12H, CHcycle), 3.14 (m, 12H, 
CHHcycle), 2.85 (m, 12H, SCHH), 2.72 (m, 12H, SCHH), 2.62 (m, 24H, NCH2CH2), 2.51 (m, 12H, 
CHHcycle), 1.91-1.53 (m, 72H, SCH2CH2, OCH2CH2, CH2CH2OCO), 1.44-1.19 (m, 120H, CH2,aliphatic 
chain), 0.87 (t, 36H, JH,H = 6.7, CH3); 13C NMR (125.8 MHz, CDCl3) δ: 176.3 (COcycle), 174.5 (COcycle), 
170.5 (COester), 163.7 (CO), 145.8 (Csp2,fullerene), 141.1 (Csp2,fullerene), 69.1 (Csp3,fullerene), 66.5 
(OCH2CH2), 64.2 (CH2CH2OCO), 45.4 (Cq), 39.1 (CHcycle), 36.2 (CH2,cycle), 34.7 (NCH2CH2), 31.9 
(NCH2CH2), 31.8 (SCH2, CH2,aliphatic chain), 29.1 (CH2,aliphatic chain), 29.0 (SCH2CH2), 28.8 (CH2,aliphatic 
chain), 25.2 (OCH2CH2) 25.1 (CH2CH2OCO), 22.6 (CH2,aliphatic chain), 14.1 (CH3); MS (MALDI-ToF) 
m/z: [M+Na]+ Calcd for C306H384N12O72S12Na 5790.2; Found 5790.4. 
Compound 5b. Following the general procedure and using 2-[2’-(2’’-
mercaptoethoxy)ethoxy]ethanol (4b) (60 mg, 0.36 mmol) as starting material, compound 5b (118 mg, 
19.66 μmol, 98%) was obtained as a red oil. FTIR: 3466, 2927, 1700, 1195, 725 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 4.26 (m, 24H, OCH2CH2), 4.04 (m, 24H, CH2CH2OCO), 3.94 (m, 12H, CHcycle), 
3.80-3.49 (m, 144H, SCH2CH2O, NCH2CH2, CH2O, OCH2CH2OH, OCH2CH2OH), 3.20-3.04 (m, 
24H, CHHcycle, SCHH), 2.82 (m, 12H, SCHH), 2.65-2.45 (m, 36H, NCH2CH2, CHHcycle), 1.82-1.55 
(m, 48H, OCH2CH2, CH2CH2OCO); 13C NMR (125.8 MHz, CDCl3) δ: 176.5 (COcycle), 174.7 
(COcycle), 170.7 (COester), 163.7 (CO), 145.7 (Csp2,fullerene), 141.1 (Csp2,fullerene), 72.5 (OCH2CH2OH), 
70.9 (SCH2CH2O), 70.3 (CH2O), 69.1 (Csp3,fullerene), 66.5 (OCH2CH2), 64.1 (CH2CH2OCO), 61.7 
(OCH2CH2OH), 45.3 (Cq), 39.5 (CHcycle), 36.3 (CH2,cycle), 34.7 (NCH2CH2), 31.9 (NCH2CH2), 31.3 
(SCH2), 25.1 (OCH2CH2) 25.0 (CH2CH2OCO); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for 
C282H336N12O108S12Na 6029.5; Found 6029.0. 
Compound 5c. Following the general procedure and using N-acetyl-L-cysteine methyl ester (4c) 
(64 mg, 0.36 mmol) as starting material, compound 5c (122 mg, 19.89 μmol, quant.) was obtained as 
a red oil. FTIR: 3368, 2957, 1778, 1701, 1204 cm-1; 1H NMR (500 MHz, CDCl3) δ: 4.82 (m, 12H, 
both isomers, CHNHAc), 4.26 (m, 24H, OCH2CH2), 4.04 (m, 24H, CH2CH2OCO), 3.88 (m, ‘12H’, 
both isomers, CHcycle), 3.82-3.61 (m, 60H, NCH2CH2, CH3,COOMe + ‘12H’, both isomers, CHcycle), 3.44, 
3.36 (2m, 12H, both isomers, SCHH), 3.20-3.05 (m, 12H, both isomers, CHHcycle + ‘12H’, both 
isomers, SCHH), 2.95 (m, ‘12H’, both isomers, SCHH), 2.70-2.50 (m, 24H, NCH2CH2 + ‘12H’, both 
isomers, CHHcycle), 2.43 (m, ‘12H’, both isomers, CHHcycle), 2.01 (s, 36H, CH3,NHAc), 1.83-1.55 (m, 
48H, OCH2CH2, CH2CH2OCO); 13C NMR (125.8 MHz, CDCl3) δ: 176.7, 176.4 (COcycle, both 
isomers), 174.2, 174.0 (COcycle, both isomers), 171.1, 171.0 (CONHAc, both isomers), 170.6 (COester), 
170.4, 170.3 (COCOOMe, both isomers), 163.7 (CO), 145.7 (Csp2,fullerene), 141.1 (Csp2,fullerene), 69.1 
(Csp3,fullerene), 66.5 (OCH2CH2), 64.2 (CH2CH2OCO), 52.9, 52.8 (CH3,COOMe, both isomers), 52.2, 51.4 
(CHNHAc, both isomers), 45.4 (Cq), 40.2, 38.8 (CHcycle, both isomers), 36.3, 35.7 (CH2,cycle, both 
isomers), 34.9 (NCH2CH2), 34.5, 33.9 (SCH2, both isomers), 31.8 (NCH2CH2), 25.1 (OCH2CH2) 25.0 
(CH2CH2OCO), 23.0 (CH3,NHAc); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C282H300N24O108S12Na 
6159.3; Found 6159.6. 
4-((Tert-butyldiphenylsilyl)oxy)butyl ethyl malonate (7). Ethyl malonyl chloride (450 μL, 
3.51 mmol) was added dropwise to a solution of 4-((tert-butyldiphenylsilyl)oxy)butan-1-ol (6) (1.27 
g, 3.87 mmol), Et3N (539 μL, 3.87 mmol) and DMAP (17 mg, 0.14 mmol) in dry CH2Cl2 (15 mL) at 
0 °C under Ar atmosphere. After 30 min, the mixture was allowed to slowly warm to room 
temperature, and stirred for 12 h. Then, the solution was diluted with CH2Cl2 and washed with 1M HCl 
and brine. The organic layer was dried with anh. MgSO4, filtered and concentrated. The resulting crude 
was purified by silica gel column chromatography (EtOAc/n-hexane, 1:10), to give 7 (1.55 g, 3.51 
mmol, quant.) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ: 7.66 (m, 4H, H-ArTBDPS), 7.40 (m, 
6H, H-ArTBDPS), 4.20 (q, 2H, JH,H = 7.1, CH2CH3), 4.16 (t, 2H, JH,H = 6.6, OCH2CH2), 3.38 (t, 2H, JH,H 
= 6.1, CH2CH2OTBDPS), 3.35 (s, 2H, Hmalonate), 1.76 (m, 2H, CH2CH2OTBDPS), 1.61 (m, 2H, 
OCH2CH2), 1.27 (t, 3H, JH,H = 7.1, CH2CH3), 1.05 (s, 9H, C(CH3)3,TBDPS); 13C NMR (100 MHz, 
CDCl3) δ: 166.7 (CO), 166.6 (CO), 135.6 (C-ArTBDPS), 133.9 (Cipso-ArTBDPS), 129.7 (C-ArTBDPS), 127.7 
(C-ArTBDPS), 65.5 (OCH2CH2), 63.3 (CH2CH2OTBDPS), 61.6 (CH2CH3), 41.7 (CH2malonate), 28.9 
(CH2CH2OTBDPS), 26.9 (C(CH3)3,TBDPS), 25.2 (OCH2CH2), 19.3 (C(CH3)3,TBDPS), 14.2 (CH2CH3); 
MS (ESI) m/z: [M+Na]+ Calcd for C25H34O5SiNa 465.2; Found 465.3; HRMS (ESI) m/z: [M+Na]+ 
Calcd for C25H34O5SiNa 465.2068; Found 465.2060. 
 
Compound 8. DBU (388 μL, 2.26 mmol) was added to a solution of fullerene C60 (1.30 g, 1.80 
mmol), malonate 7 (400 mg, 0.90 mmol) and I2 (803 mg, 3.17 mmol) in dry toluene (300 mL) at 0 °C 
under Ar atmosphere. The resulting solution was stirred at 0 °C for 4 h. After this time, Na2S2O3 sat. 
aq. soln. (50 mL) was added, and the organic layer was successively washed with 0.5 M HCl, and 
brine, dried over anh. MgSO4, filtered and concentrated. The resulting crude was purified by silica gel 
column chromatography (CH2Cl2/n-hexane, 1:1), furnishing monoadduct 8 (720 mg, 0.62 mmol, 69%) 
as a brown solid. mp = 100 ºC (desc); FTIR: 3474, 3067, 2929, 2858, 2329, 1744, 1235 cm-1; 1H NMR 
(500 MHz, CDCl3) δ: 7.69 (m, 4H, H-ArTBDPS), 7.42 (m, 6H, H-ArTBDPS), 4.55 (q, 2H, JH,H = 7.1, 
CH2CH3), 4.53 (t, 2H, JH,H = 6.7, OCH2CH2), 3.75 (t, 2H, JH,H = 6.2, CH2CH2OTBDPS), 1.98 (m, 2H, 
CH2CH2OTBDPS), 1.77 (m, 2H, OCH2CH2), 1.48 (t, 3H, JH,H = 7.1, CH2CH3), 1.08 (s, 9H, 
C(CH3)3,TBDPS); 13C NMR (125.8 MHz, CDCl3) δ: 163.7 (CO), 163.6 (CO), 145.5 (Csp2,fullerene), 145.4 
(Csp2,fullerene), 145.3 (Csp2,fullerene), 145.2 (Csp2,fullerene), 145.1 (Csp2,fullerene), 145.0 (Csp2,fullerene), 144.9 
(Csp2,fullerene), 144.8 (Csp2,fullerene), 144.7 (Csp2,fullerene), 144.6 (Csp2,fullerene), 143.9 (Csp2,fullerene), 143.3 
(Csp2,fullerene), 143.2 (Csp2,fullerene), 143.1 (Csp2,fullerene), 143.0 (Csp2,fullerene), 142.3 (Csp2,fullerene), 142.0 
(Csp2,fullerene), 141.9 (Csp2,fullerene), 141.0 (Csp2,fullerene), 140.9 (Csp2,fullerene), 139.2 (Csp2,fullerene), 139.0 
(Csp2,fullerene), 135.6 (C-ArTBDPS), 133.8 (Cipso-ArTBDPS), 129.8 (C-ArTBDPS), 127.8 (C-ArTBDPS), 71.7 
(Csp3,fullerene), 67.3 (OCH2CH2), 63.5 (CH2CH3), 63.3 (CH2CH2OTBDPS), 52.3 (Cq), 29.0 
(CH2CH2OTBDPS), 27.0 (C(CH3)3,TBDPS), 25.4 (OCH2CH2), 19.3 (C(CH3)3,TBDPS), 14.4 (CH2CH3); 
MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C85H32O5SiNa 1183.2; Found 1183.2. 
 
Compound 10. DBU (902 μL, 6.03 mmol) was added to a solution of monoadduct 8 (350 mg, 
0.30 mmol), malonate 9 (1.29 g, 3.02 mmol) and CBr4 (8.20 g, 24.13 mmol) in dry ODCB (60 mL) 
under Ar atmosphere. The mixture was stirred for 72 h at room temperature and evaporated. The 
resulting crude was purified by silica gel column chromatography (toluene/acetone, 30:1 → 15:1), 
yielding hexakis-adduct 10 (480 mg, 0.15 mmol, 48%) as a red  oil. FTIR: 2928, 2858, 1744, 1215 
cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.66 (m, 4H, H-ArTBDPS), 7.38 (m, 6H, H-ArTBDPS), 7.35-7.21 
(m, 50H, H-Ar), 4.46 (s, 20H, CH2,Bn), 4.36-4.13 (m, 24H, OCH2CH2, CH2CH3), 3.68 (t, 2H, JH,H = 
5.9, CH2CH2OTBDPS), 3.45 (t, 20H, JH,H = 6.0, CH2CH2OBn), 1.77 (m, 22H, OCH2CH2), 1.71-1.58 
(m, 22H, CH2CH2OBn, CH2CH2OTBDPS), 1.25 (t, 3H, JH,H = 7.1, CH2CH3), 1.05 (s, 9H, 
C(CH3)3,TBDPS); 13C NMR (125.8 MHz, CDCl3) δ: 163.6 (CO), 145.7 (Csp2,fullerene), 141.0 (Csp2,fullerene), 
138.4 (Cipso-Ar), 135.4 (C-ArTBDPS), 133.6 (Cipso-ArTBDPS), 129.5 (C-ArTBDPS), 128.2 (C-Ar), 127.6 (C-
ArTBDPS), 127.4 (C-Ar), 127.3 (C-Ar), 72.7 (CH2,Bn), 69.3 (CH2CH2OBn), 69.0 (Csp3,fullerene), 66.6 
(OCH2CH2), 63.0 (CH2CH3), 62.7 (CH2CH2OTBDPS), 45.4 (Cq), 28.6 (CH2CH2OTBDPS), 26.8 
(C(CH3)3,TBDPS), 25.9 (CH2CH2OBn), 25.2 (OCH2CH2), 24.9 (OCH2CH2), 19.1 (C(CH3)3,TBDPS), 13.9 
(CH2CH3); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C210H182O35SiNa 3216.8; Found 3316.1. 
Compound 11. A solution of 10 (480 mg, 0.15 mmol) in a mixture of EtOAc/MeOH (16 mL, 
3:1) was hydrogenated under atmospheric pressure at room temperature overnight using Pd-C (10%) 
as catalyst. Then, the solution was filtered through Celite, and the catalyst was washed with MeOH. 
The filtered solution was concentrated, furnishing 11 (350 mg, 0.15 mmol, quant.) as a red solid. mp 
= 98 ºC (desc.); FTIR: 3347, 2929, 2861, 1737, 1214 cm-1; 1H NMR (500 MHz, CD3OD + εCDCl3) 
δ: 7.66 (m, 4H, H-ArTBDPS), 7.41 (m, 6H, H-ArTBDPS), 4.46-4.18 (m, 24H, OCH2CH2, CH2CH3), 3.71 
(t, 2H, JH,H = 6.0, CH2CH2OTBDPS), 3.56 (m, 20H, CH2CH2OH), 1.78 (m, 22H, OCH2CH2), 1.69-
1.51 (m, 22H, CH2CH2OH, CH2CH2OTBDPS), 1.29 (t, 3H, JH,H = 7.1, CH2CH3), 1.04 (s, 9H, 
C(CH3)3,TBDPS); 13C-NMR (125.8 MHz, CD3OD + εCDCl3) δ: 164.6 (CO), 146.6 (Csp2,fullerene), 142.4 
(Csp2,fullerene), 136.5 (C-ArTBDPS), 134.7 (Cipso-ArTBDPS), 130.8 (C-ArTBDPS), 128.7 (C-ArTBDPS), 70.4 
(Csp3,fullerene), 68.1 (OCH2CH2), 64.2 (CH2CH2OTBDPS, CH2CH3), 62.2 (CH2CH2OH), 47.3 (Cq), 29.8 
(CH2CH2OH), 29.6 (CH2CH2OTBDPS), 27.4 (C(CH3)3,TBDPS), 26.1 (OCH2CH2),  20.0 
(C(CH3)3,TBDPS), 14.6 (CH2CH3); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C140H122O35SiNa 
2414.7; Found 2414.7.  
Compound 13. To a solution of 11 (170 mg, 71.11 μmol), cyclooctyne derivative 12 (333 mg, 
1.07 mmol) in a mixture of dry CH2Cl2/DMF (3.4 mL, 7.5:1) under Ar atmosphere, a solution of DCC 
(171 mg, 0.82 mmol) in dry CH2Cl2 (2 mL) and DMAP (4.4 mg, 35.55 μmol) were sequentially added. 
The reaction mixture was stirred at room temperature overnight. Once the reaction was complete, the 
dicyclohexylurea was filtered off in a fritted glass filter and washed with CH2Cl2. The crude product 
was purified by size-exclusion chromatography (Sephadex LH-20, MeOH/CH2Cl2 1:1), to give 13 
(377 mg, 70.70 μmol, quant.) as a red oil. FTIR: 2927, 2857, 1734, 1213 cm-1; 1H NMR (500 MHz, 
CDCl3) δ: 7.64 (m, 4H, H-ArTBDPS), 7.38 (m, 6H, H-ArTBDPS), 4.33-4.25 (m, 24H, OCH2CH2, 
CH2CH3), 4.25-4.17 (m, 30H, H-1, CH2O), 4.10 (m, 20H, CH2CH2OCO), 3.74-3.65 (m, 32H, CHHO, 
CH2O, CH2CH2OTBDPS), 3.63 (m, 20H, CH2O), 3.48 (m, 10H, CHHO), 2.68-2.56 (m, 40H, 
CH2,succ.), 2.23 (m, 10H, H-6a), 2.18-2.06 (m, 20H, H-2a, H-6b), 2.00-1.86 (m, 20H, H-2b, H-5a), 
1.85-1.62 (m, 72H, H-3a, H-4a, H-5b, OCH2CH2, CH2CH2OCO), 1.62-1.53 (m, 12H, H-4b, 
CH2CH2OTBDPS), 1.41 (m, 10H, H-3b), 1.26 (t, 3H, JH,H = 7.1, CH2CH3), 1.03 (s, 9H, 
C(CH3)3,TBDPS); 13C NMR (125.8 MHz, CDCl3) δ: 171.9 (COsucc), 171.8 (COsucc), 163.3 (CO), 145.5 
(Csp2,fullerene), 140.8 (Csp2,fullerene), 135.2 (C-ArTBDPS), 133.4 (Cipso-ArTBDPS), 129.4 (C-ArTBDPS), 127.4 
(C-ArTBDPS), 99.7 (C-7), 92.5 (C-8), 72.4 (C-1), 70.1 (CH2O), 68.8 (Csp3,fullerene), 68.7 (CH2O), 68.2 
(CH2O), 66.1 (OCH2CH2), 63.6 (CH2CH2OCO), 63.5 (CH2O), 62.9 (CH2CH3), 62.7 
(CH2CH2OTBDPS), 45.0 (Cq), 42.0 (C-2), 34.0 (C-5), 29.5 (C-4), 28.8 (CH2,succ., CH2CH2OTBDPS), 
26.6 (C(CH3)3,TBDPS), 26.1 (C-3), 24.8 (OCH2CH2CH2CH2OCO), 20.4 (C-6), 18.9 (C(CH3)3,TBDPS), 
13.8 (CH2CH3); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C300H342O85SiNa 5358.1; Found 5358.1. 
Compound 14. A cold solution of HF-pyridine complex (375 μL), was slowly added to a 
mixture of compound 13 (375 mg, 70.33 μmol) and AcOH (90 μL) in THF (2 mL). The reaction 
mixture was stirred at room temperature overnight. The crude product was purified by size-exclusion 
chromatography (Sephadex LH-20, MeOH/CH2Cl2 1:1), to give 14 (355 mg, 69.69 μmol, 99%) as a 
red oil. FTIR: 2928, 2857, 1735, 1214 cm-1; 1H NMR (500 MHz, CDCl3) δ: 4.37-4.26 (m, 24H, 
OCH2CH2, CH2CH3), 4.26-4.17 (m, 30H, H-1, CH2O), 4.10 (m, 20H, CH2CH2OCO), 3.75-3.66 (m, 
30H, CHHO, CH2O), 3.66-3.58 (m, 22H, CH2O, CH2CH2OH), 3.49 (m, 10H, CHHO), 2.69-2.57 (m, 
40H, CH2,succ.), 2.24 (m, 10H, H-6a), 2.19-2.07 (m, 20H, H-2a, H-6b), 2.01-1.87 (m, 20H, H-2b, H-
5a), 1.86-1.63 (m, 72H, H-3a, H-4a, H-5b, OCH2CH2, CH2CH2OCO), 1.63-1.54 (m, 12H, H-4b, 
CH2CH2OH), 1.42 (m, 10H, H-3b), 1.32 (t, 3H, JH,H = 7.1, CH2CH3); 13C NMR (125.8 MHz, CDCl3) 
δ: 172.2 (COsucc), 172.1 (COsucc), 163.6 (CO), 145.7 (Csp2,fullerene), 141.0 (Csp2,fullerene), 100.0 (C-7), 92.7 
(C-8), 72.7 (C-1), 70.3 (CH2O), 69.0 (Csp3,fullerene), 68.9 (CH2O), 68.4 (CH2O), 66.4 (OCH2CH2), 63.9 
(CH2CH2OCO), 63.8 (CH2O, CH2CH3), 61.9 (CH2CH2OH), 45.3 (Cq), 42.2 (C-2), 34.2 (C-5), 29.7 
(C-4), 28.9 (CH2,succ.), 26.3 (C-3), 25.1 (OCH2CH2CH2CH2OCO, CH2CH2OH), 20.6 (C-6), 14.0 
(CH2CH3); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C284H324O85Na 5120.6; Found 5120.0. 
Compound 15. To a solution of 14 (340 mg, 66.74 μmol) and 3-maleimidopropionic acid (5) 
(22.6 mg, 0.13 mmol) in dry CH2Cl2 (3 mL) under Ar atmosphere, a solution of DCC (42 mg, 0.20 
mmol) in dry CH2Cl2 (1 mL) and DMAP (0.8 mg, 6.67 μmol) were sequentially added. The reaction 
mixture was stirred at room temperature overnight. Once the reaction was complete the 
dicyclohexylurea was filtered off in a fritted glass filter and washed with CH2Cl2. The crude product 
was purified by size-exclusion chromatography (Sephadex LH-20, MeOH/CH2Cl2 1:1), to give 15 
(349 mg, 66.54 μmol, quant.) as a red oil. FTIR: 2928, 2857, 1733, 1212 cm-1; 1H NMR (500 MHz, 
CDCl3) δ: 6.70 (s, 2H, Hmaleimide), 4.37-4.25 (m, 24H, OCH2CH2, CH2CH3), 4.25-4.17 (m, 30H, H-1, 
CH2O), 4.10 (m, 22H, CH2CH2OCO), 3.81 (t, 2H, JH,H = 6.9, NCH2CH2), 3.74-3.66 (m, 30H, CHHO, 
CH2O), 3.63 (m, 20H, CH2O), 3.49 (m, 10H, CHHO), 2.70-2.55 (m, 42H, CH2,succ., NCH2CH2), 2.23 
(m, 10H, H-6a), 2.19-2.07 (m, 20H, H-2a, H-6b), 2.00-1.87 (m, 20H, H-2b, H-5a), 1.86-1.63 (m, 74H, 
H-3a, H-4a, H-5b, OCH2CH2, CH2CH2OCO), 1.58 (m, 10H, H-4b), 1.42 (m, 10H, H-3b), 1.31 (t, 3H, 
JH,H = 7.1, CH2CH3); 13C NMR (125.8 MHz, CDCl3) δ: 172.1 (COsucc), 172.0 (COsucc), 170.5 (COester), 
170.2 (COmaleimide), 163.5 (CO), 145.6 (Csp2,fullerene), 140.9 (Csp2,fullerene), 134.2 (CHmaleimide), 99.9 (C-7), 
92.6 (C-8), 72.6 (C-1), 70.2 (CH2O), 68.9 (Csp3,fullerene), 68.8 (CH2O), 68.3 (CH2O), 66.3 (OCH2CH2), 
63.8 (CH2CH2OCO), 63.7 (CH2O, CH2CH3), 45.2 (Cq), 42.1 (C-2), 34.2 (C-5), 33.5 (NCH2CH2), 32.8 
(NCH2CH2), 29.6 (C-4), 28.8 (CH2,succ.), 26.2 (C-3), 25.0 (OCH2CH2CH2CH2OCO), 20.6 (C-6), 14.0 
(CH2CH3); MS (MALDI-ToF) m/z: [M+Na]+ Calcd for C291H329NO88Na 5271.7; Found 5271.1.  
Compound 16. To a solution of hexakis adduct 15 (100 mg, 19.07 μmol) in DMSO (2 mL), 2-
(2-(2-azidoethoxy)ethoxy)ethan-1-ol (50 mg, 0.29 mmol) was added. The reaction mixture was stirred 
at room temperature overnight. The solution was purified by size-exclusion chromatography 
(Sephadex LH-20, CH2Cl2/MeOH 1:1), furnishing  compound 16 (132 mg, 18.87 μmol, 99%) as a red 
oil. FTIR: 3459, 2925, 2862, 1735, 1216 cm-1; 1H NMR (500 MHz, CDCl3) δ: 6.64 (s, 2H, Hmaleimide), 
4.76 (m, 10H, both isomers, H-1), 4.52 (m, ‘20H’, mi., OCH2CH2N), 4.30 (m, ‘20H’, mj., 
OCH2CH2N), 4.27-4.18 (m, 24H, OCH2CH2, CH2CH3), 4.14 (m, 20H, CH2O), 4.02 (m, 22H, 
CH2CH2OCO), 3.84 (m, 20H, OCH2CH2N), 3.73 (m, 2H, NCH2CH2), 3.67-3.38 (m, 140H, 
OCH2CH2OH, OCH2CH2OH, CH2O), 3.01, 2.74, 2.62 (3m, 20H, both isomers, H-6), 2.59-2.48 (m, 
42H, CH2,succ., NCH2CH2), 2.10 (m, ‘20H’, both isomers, H-2a), 1.93 (m, ‘20H’, mi., H-2b), 1.79-1.37 
(m, 84H, OCH2CH2, CH2CH2OCO, H-3, H-5 + ‘20H’, both isomers, H-4 + ‘20H’, mj., H-2b), 1.23 
(m, 3H, CH2CH3), 1.16, 0.94 (2m, ‘20H’, both isomers, H-4); 13C NMR (125.8 MHz, CDCl3) δ: 172.2 
(COsucc), 172.1 (COsucc), 170.6 (COester), 170.2 (COmaleimide), 163.6 (CO), 145.7 (Csp2,fullerene), 144.6 (C-
7, mj.), 144.2 (C-8, mi.), 140.9 (Csp2,fullerene), 134.8 (C-8, mj.), 134.2 (CHmaleimide), 133.6 (C-7, mi.), 
74.5 (C-1, mj.), 72.4 (OCH2CH2OH), 71.9 (C-1, mi.), 70.6 (CH2O), 70.5 (CH2O), 70.4 (CH2O), 
70.3(CH2O), 70.2 (CH2O), 70.0, 69.7 (OCH2CH2N, both isomers), 68.9, 68.8 (CH2O, both isomers, 
Csp3,fullerene), 67.7, 67.4 (CH2O, both isomers), 66.3 (OCH2CH2), 63.8-63.6 (CH2CH2OCO, CH2CH3 + 
CH2O, both isomers), 61.5 (OCH2CH2OH), 48.4 (OCH2CH2N, mi.), 47.3 (OCH2CH2N, mj.), 45.2 
(Cq), 35.4 (C-2, mj.), 33.5 (NCH2CH2), 32.8 (NCH2CH2), 30.8 (C-2, mi.), 28.8 (CH2,succ.), 28.7 
(CH2,succ.), 28.0 (C-5, mi.), 26.9 (C-5, mj.), 25.4 (C-4, mj.), 25.0 (OCH2CH2CH2CH2OCO), 24.4 (C-
4, mi.), 24.2 (C-6, mi.), 22.8 (C-3, mi.), 20.7 (C-3, mj.), 19.9 (C-6, mj.), 14.0 (CH2CH3); MS (MALDI-
ToF) m/z: [M+Na]+ Calcd for C351H459N31O118Na 7022.6; Found 7022.8.  
Compound 18. To a solution of hexakis adduct 15 (100 mg, 19.07 μmol) in DMF (2 mL), 1-
octanethiol (5.8 mg, 38.14 μmol) was added. After 30 min of stirring at room temperature, the solution 
was purified by size-exclusion chromatography (Sephadex LH-20, CH2Cl2/MeOH 1:1), furnishing 
compound 18 (102 mg, 18.92 μmol, 99%) as a red oil. FTIR: 2926, 2854, 1732, 1210 cm-1. 1H NMR 
(500 MHz, CDCl3) δ: 4.32-4.22 (m, 24H, OCH2CH2, CH2CH3), 4.22-4.14 (m, 30H, H-1, CH2O), 4.06 
(m, 22H, CH2CH2OCO), 3.86-3.72 (m, 3H, NCH2CH2, CHcycle), 3.70-3.62 (m, 30H, CHHO, CH2O), 
3.60 (m, 20H, CH2O), 3.45 (m, 10H, CHHO), 3.09 (m, 1H, CHHcycle), 2.82 (m, 1H, SCHH), 2.69 (m, 
1H, SCHH), 2.64-2.53 (m, 42H, CH2,succ., NCH2CH2), 2.46 (m, 1H, CHHcycle), 2.20 (m, 10H, H-6a), 
2.15-2.03 (m, 20H, H-2a, H-6b), 1.96-1.84 (m, 20H, H-2b, H-5a), 1.82-1.60 (m, 74H, H-3a, H-4a, H-
5b, OCH2CH2, CH2CH2OCO), 1.60-1.50 (m, 12H, H-4b, SCH2CH2), 1.38 (m, 10H, H-3b), 1.30-1.17 
(m, 13H, CH2,aliphatic chain, CH2CH3), 0.83 (m, 3H, CH3,aliphatic chain); 13C NMR(125.8 MHz, CDCl3) δ: 
176.2 (COcycle), 174.4 (COcycle), 172.3 (COsucc), 172.2 (COsucc), 170.5 (COester), 163.7 (CO), 
145.8(Csp2,fullerene), 141.0 (Csp2,fullerene), 100.1 (C-7), 92.8 (C-8), 72.8 (C-1), 70.4 (CH2O), 69.1 
(Csp3,fullerene), 69.0 (CH2O), 68.5 (CH2O), 66.4 (OCH2CH2), 63.9 (CH2CH2OCO), 63.8 (CH2O, 
CH2CH3), 45.3 (Cq), 42.3 (C-2), 39.0 (CHcycle), 36.1 (CH2,cycle), 34.7 (NCH2CH2), 34.3 (C-5), 31.9 
(NCH2CH2), 31.8 (SCH2), 31.7 (CH2,aliphatic chain), 29.7 (C-4), 29.6 (SCH2CH2), 29.1 (CH2,aliphatic chain), 
29.0 (CH2,succ., CH2,aliphatic chain), 28.8 (CH2,aliphatic chain), 26.4 (C-3), 25.1 (OCH2CH2CH2CH2OCO), 22.6 
(CH2,aliphatic chain), 20.7 (C-6), 14.1 (CH2CH3, CH3,aliphatic chain); MS (MALDI-ToF) m/z: [M+Na]+ Calcd 
for C299H347NO88SNa 5417.1; Found 5417.3.  
Compound 17a. 
From 18: Hexakis adduct 18 (100 mg, 18.55 μmol) and 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (49 
mg, 0.28 mmol) were dissolved in DMSO (1 mL) in a sealed microwave vial. The solution was heated 
at 50 °C in a microwaves oven for 30 min. The solution was purified by size-exclusion 
chromatography (Sephadex LH-20, CH2Cl2/MeOH 1:1), furnishing compound 17a (131 mg, 18.34 
μmol, 99%) as a red oil. 
Consecutive approach: To a solution of hexakis adduct 15 (100 mg, 19.07 μmol) in DMF (1 mL) in a 
sealed microwave vial, 1-octanethiol (5.8 mg, 38.14 μmol) was added. After 30 min of stirring at room 
temperature, 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (50 mg, 0.29 mmol) was added. The reaction 
mixture was heated at 50 °C in a microwaves oven for 30 min. The solution was purified by size-
exclusion chromatography (Sephadex LH-20, CH2Cl2/MeOH 1:1), furnishing  compound 17a (136 
mg, 19.04 μmol, quant.) as a red oil. FTIR: 3468, 2925, 2863, 1733, 1218 cm-1; 1H NMR (500 MHz, 
CDCl3) δ: 4.77 (m, 10H, both isomers, H-1), 4.54 (m, ‘20H’, mi., OCH2CH2N), 4.32 (m, ‘20H’, mj., 
OCH2CH2N), 4.28-4.19 (m, 24H, OCH2CH2, CH2CH3), 4.15 (m, 20H, CH2O), 4.04 (m, 22H, 
CH2CH2OCO), 3.85 (m, 20H, OCH2CH2N), 3.77-3.70 (m, 3H, NCH2CH2, CHcycle), 3.68-3.39 (m, 
140H, OCH2CH2OH, OCH2CH2OH, CH2O), 3.12-2.95 (m, 1H, CHHcycle + ‘20H’, both isomers, H-
6), 2.76, 2.64 (2m, 2H, SCH2 + ‘20H’, both isomers, H-6), 2.61-2.50 (m, 42H, CH2,succ., NCH2CH2), 
2.44 (m, 1H, CHHcycle), 2.11 (m, ‘20H’, both isomers, H-2a), 1.94 (m, ‘20H’, mi., H-2b), 1.81-1.40 
(m, 86H, OCH2CH2, CH2CH2OCO, H-3, H-5, SCH2CH2 + ‘20H’, both isomers, H-4 + ‘20H’, mj., H-
2b), 1.36-1.09 (m, 13H, CH2,aliphatic chain, CH2CH3 + ‘20H’, both isomers, H-4), 0.96 (m, ‘20H’, both 
isomers, H-4), 0.80 (m, 3H, CH3,aliphatic chain); 13C NMR (125.8 MHz, CDCl3) δ: 176.2 (COcycle), 174.4 
(COcycle), 172.2 (COsucc), 172.1 (COsucc), 170.5 (COester), 163.6 (CO), 145.7 (Csp2,fullerene), 144.6 (C-7, 
mj.), 144.2 (C-8, mi.), 141.0 (Csp2,fullerene), 134.8 (C-8, mj.), 133.7 (C-7, mi.), 74.5 (C-1, mj.), 72.4 
(OCH2CH2OH), 71.9 (C-1, mi.), 70.6 (CH2O), 70.5 (CH2O), 70.4 (CH2O), 70.3 (CH2O), 70.2 (CH2O), 
70.0, 69.8 (OCH2CH2N, both isomers), 69.0, 68.8 (CH2O, both isomers, Csp3,fullerene), 67.7, 67.4 
(CH2O, both isomers), 66.4 (OCH2CH2), 63.9, 63.8, 63.7 (CH2CH2OCO, CH2CH3 + CH2O, both 
isomers), 61.5 (OCH2CH2OH), 48.4 (OCH2CH2N, mi.), 47.4 (OCH2CH2N, mj.), 45.2 (Cq), 39.0 
(CHcycle), 36.1 (CH2,cycle), 35.5 (C-2, mj.), 34.6 (NCH2CH2), 33.8 (NCH2CH2), 31.8 (SCH2), 31.7 
(CH2,aliphatic chain), 30.8 (C-2, mi.), 29.6 (SCH2CH2), 29.0 (CH2,aliphatic chain), 28.9, 28.8 (CH2,succ., 
CH2,aliphatic chain), 28.7 (CH2,aliphatic chain), 28.1 (C-5, mi.), 26.9 (C-5, mj.), 25.5 (C-4, mj.), 25.0 
(OCH2CH2CH2CH2OCO), 24.4 (C-4, mi.), 24.3 (C-6, mi.), 22.9 (C-3, mi.), 22.6 (CH2,aliphatic chain), 20.8 
(C-3, mj.), 19.9 (C-6, mj.), 14.0 (CH2CH3, CH3,aliphatic chain); MS (MALDI-ToF) m/z: [M+Na]+ Calcd 
for C359H477N31O118SNa 7169.9; Found 7169.1. 
Compound 17b. To a solution of hexakis adduct 15 (100 mg, 19.07 μmol) in DMF (2 mL) in a 
sealed microwave vial, N-acetyl-L-cysteine methyl ester (4c) (7.5 mg, 38.14 μmol) was added. After 
30 min of stirring at room temperature, compound 19 (97 mg, 0.29 mmol) was added. The reaction 
mixture was heated at 50 °C in a microwaves oven for 30 min. The solution was purified by size-
exclusion chromatography (Sephadex G-25, H2O/MeOH 9:1), furnishing compound 17b (136 mg, 
19.04 μmol, quant.) as a red oil. FTIR: 3377, 2926, 1731, 1239, 1023 cm-1; 1H NMR (500 MHz, 
DMSO-d6) δ: 4.85 (m, ‘10H’, mi., H-1), 4.72 (m, ‘10H’, mj., H-1), 4.62 (m, 10H, H-1man), 4.60-4.46 
(m, 1H, both isomers, CHNHAc + ‘20H’, mi., OCH2CH2N), 4.39 (m, ‘20H’, mj., OCH2CH2N), 4.35-
4.19 (m, 24H, OCH2CH2, CH2CH3), 4.11 (m, 20H, CH2O), 4.06-3.93 (m, 23H, both isomers, CHcycle, 
CH2CH2OCO), 3.78 (m, 20H, OCH2CH2N), 3.68-3.34 (m, 195H, NCH2CH2, CH3,COOMe, CH2O, H-
2man, H-3man, H-5man, H-6man), 3.33-3.27 (m, 11H, both isomers, SCHH, H-4man), 3.07-2.87 (m, 2H, 
both isomers, CHHcycle, both isomers, SCHH + ‘20H’, both isomers, H-6), 2.74 (m, ‘20H’, both 
isomers, H-6), 2.59-2.51 (m, 42H, CH2,succ., NCH2CH2), under DMSO-d6 (m, 1H, both isomers, 
CHHcycle), 2.13 (m, ‘20H’, mi., H-2a), 1.99 (m, ‘20H’, mj., H-2a), 1.92 (m, ‘20H’, mi., H-2b), 1.86 
(m, 3H, CH3,NHAc),  1.78-1.36 (m, 84H, OCH2CH2, CH2CH2OCO, H-3, H-5 + ‘20H’, both isomers, H-
4 + ‘20H’, mj., H-2b), 1.22 (m, 3H, CH2CH3),  1.13, 0.98 (2m, ‘20H’, both isomers, H-4); 13C NMR 
(125.8 MHz, DMSO-d6) δ: 176.4, 176.3 (COcycle, both isomers), 174.7, 174.6 (COcycle, both isomers), 
172.0 (COsucc), 171.9 (COsucc), 171.1, 171.0 (CONHAc, both isomers), 170.4 (COester), 169.6, 169.4 
(COCOOMe, both isomers), 162.8 (CO), 145.0 (Csp2,fullerene), 143.8 (C-7, mj.), 143.1 (C-8, mi.), 140.7 
(Csp2,fullerene), 134.5 (C-8, mj.), 133.8 (C-7, mi.), 100.0 (C-1man), 73.9 (C-4man, C-1, mj.), 71.0 (C-3man), 
70.7 (C-1, mi.), 70.3 (C-2man), 69.9-69.5 (CH2O), 69.4, 69.3 (OCH2CH2N, both isomers), 68.7 
(Csp3,fullerene), 68.3, 68.2 (CH2O, both isomers), 67.3, 67.1 (CH2O, both isomers), 67.0 (C-5man), 66.7 
(OCH2CH2), 65.7 (CH2O), 63.5 (CH2O), 63.4 (CH2CH2OCO, CH2CH3), 61.3 (C-6man), 52.2, 52.1 
(CH3,COOMe, both isomers), 52.0, 51.5 (CHNHAc, both isomers), 47.9 (OCH2CH2N, mi.), 47.0 
(OCH2CH2N, mj.), 45.6 (Cq), under DMSO-d6 (CHcycle, both isomers), 35.8, 35.6 (CH2,cycle, both 
isomers), 35.0 (C-2, mj.), 33.5 (NCH2CH2), 32.2, 32.1 (SCH2, both isomers), 31.4 (NCH2CH2), 30.3 
(C-2, mi.), 28.5 (CH2,succ.), 27.9 (C-5, mi.), 26.4 (C-5, mj.), 25.3 (C-4, mj.), 24.6 
(OCH2CH2CH2CH2OCO), 23.9 (C-4, mi.), 23.6 (C-6, mi.), 22.3 (CH3,NHAc), 22.2 (C-3, mi.), 20.8 (C-
3, mj.), 19.5 (C-6, mj.), 13.7 (CH2CH3); MS (MALDI-ToF) m/z: [M]+ Calcd for C417H590N32O171S 
8819.4; Found: high level of occurring fragmentation avoided the observation of the expected 
molecular ion peak. 
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